OnePin Peptide Library · Immune
TA-1
Thymalfasin · Thymosin Alpha-1 · TA1 · Zadaxin
Thymosin Alpha-1 (TA-1) is a 28-amino acid peptide naturally produced by the thymus gland that plays a central role in adaptive immune function. It is one of the few peptides with FDA/international regulatory approval, marketed as Zadaxin in over 30 countries for the treatment of hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy and vaccination protocols. TA-1 enhances T-cell maturation, natural killer cell activity, dendritic cell function, and cytokine production. It bridges innate and adaptive immunity by promoting the differentiation of immature T-cells into functional CD4+ and CD8+ effector cells. TA-1 is discussed in longevity, immune optimization, and chronic infection protocols as one of the best-characterized immune-modulating peptides available.
Any time of day. No fasting required. Continuous use safe at 2x/week. For acute immune challenge, daily dosing for 5-7 days.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
TA-1 acts on thymic progenitor cells to promote T-cell differentiation and maturation. It activates toll-like receptors (TLR2, TLR9) on dendritic cells, enhancing antigen presentation to T-cells. TA-1 increases production of IL-2 and IFN-alpha, key cytokines for T-cell proliferation and antiviral defense. It promotes CD4+ helper T-cell and CD8+ cytotoxic T-cell differentiation, enhances natural killer cell cytotoxicity, stimulates dendritic cell maturation for improved antigen presentation, and modulates Th1/Th2 balance toward appropriate immune responses. TA-1 also opposes immune senescence (the age-related decline in thymic function and T-cell diversity) by partially restoring thymic output in aged individuals.
TA-1 acts on thymic progenitor cells to promote T-cell differentiation and maturation. It activates toll-like receptors (TLR2, TLR9) on dendritic cells, enhancing antigen presentation to T-cells. TA-1 increases production of IL-2 and IFN-alpha, key cytokines for T-cell proliferation and antiviral defense. It promotes CD4+ helper T-cell and CD8+ cytotoxic T-cell differentiation, enhances natural killer cell cytotoxicity, stimulates dendritic cell maturation for improved antigen presentation, and modulates Th1/Th2 balance toward appropriate immune responses. TA-1 also opposes immune senescence (the age-related decline in thymic function and T-cell diversity) by partially restoring thymic output in aged individuals.
What to expect
Days 1-7: No immediate subjective effects expected. Immune cell changes begin at the cellular level.
Weeks 2-4: T-cell maturation and NK cell activation become functionally relevant. Immune resilience begins to improve. Lab markers may show changes.
Weeks 4-12: Full immune optimization. Reduced frequency and severity of infections. Vaccination responses enhanced. Best assessed through immune panel labwork.
Evidence
The honest take
Immune enhancement
Strongest claim. FDA/international approval as immune adjuvant. Phase 3 clinical trial data. One of the only peptides with this level of regulatory validation for immune claims.
Approved as adjuvant in melanoma treatment in several countries. Clinical data supports improved outcomes when combined with standard cancer treatments. Not a standalone cancer treatment.
Thymic involution is a hallmark of aging. TA-1 partially restores thymic output. Conceptually sound for immune aging but not studied in longevity-specific trials.
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Keep separate
Side effects & safety
Commonly reported
- Very well tolerated (FDA-approved medication)
- Mild injection site reaction
- Rare flu-like symptoms (immune activation, usually transient)
Less common & notes
- Zadaxin has an established safety profile from international clinical use.
- Rare hypersensitivity reactions.
- Transient flu-like symptoms during initial immune activation.
- Individuals with autoimmune conditions should consult their physician as immune enhancement could theoretically exacerbate autoimmune activity.
- Organ transplant recipients on immunosuppression should not use TA-1 without physician guidance.
Pharmacokinetics
Storage. Store unreconstituted vials frozen (-20C) or refrigerated (2-8C). After reconstitution with BAC water, refrigerate at 2-8C. Stable for 28-30 days. FDA-approved formulation has well-characterized stability. Protect from light.
Regulatory status
Approved as Zadaxin in over 30 countries for hepatitis B/C treatment and as immune adjuvant. Not FDA-approved in the United States (application was filed but not pursued commercially). WADA does not specifically prohibit TA-1. Available through compounding pharmacies and research channels.
Put it to work
Calculate, log & track
Open TA-1 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open TA-1 in the app →Go deeper
The guide & community
The complete TA-1 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗